AI-generated summary
The authors reviewed 18 studies of photobiomodulation in acute traumatic brain injury, seventeen in animal models and one in human patients. They report that the single human study supports safety and feasibility in acute moderate injury, and that pooled animal data favored treatment for neurological severity score and lesion size. Favorable parameters included wavelengths near 665 and 810 nm, early first treatment, and up to three daily treatments.
- Studies included
- 18
- Who or what was studied
- Acute traumatic brain injury in pre-clinical animal models (seventeen studies) and human patients with acute moderate TBI (one study)
- Wavelengths
- 665, 810 nm
- Limits stated in the abstract
- The abstract does not report certainty of evidence, and the human evidence rests on a single clinical study.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 665 nm, 810 nm
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Traumatic brain injury, Systematic review, Meta-analysis, Brain injury. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.